MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

Discover the fascinating history of Disneyland's Matterhorn and what once existed in its place. Uncover the stories and ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Explore Switzerland’s Zermatt, as well as Chamonix in France, for thrills on the slopes and mind-blowing scenery.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...

The Meet the Sheep app was launched in 2022 and, in the first year during the peak month of August, 3000 people logged on; in ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...